Device clinical trial database
This article was originally published in The Gray Sheet
Health Industry Manufacturers Association requests in a July 14 letter to FDA a 30-day extension of the comment period pertaining to the agency's June 22 notice seeking input on the feasibility of including medical device clinical trials in a public data bank. FDA held a public meeting July 8 to gather input on the issue (1"The Gray Sheet" July 12, p. 27). Because the agency is required by the FDA Modernization Act to submit a recommendation to Congress on the subject by Nov. 21, FDA may hesitate to extend the current Aug. 23 deadline
You may also be interested in...
Inclusion of device clinical trial information in a mandatory, public database could stifle technological innovation in the device industry, trade association reps cautioned at a July 8 public meeting sponsored by FDA.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.